No Data
No Data
Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation
Wedbush Initiates Astria Therapeutics Inc(ATXS.US) With Buy Rating, Announces Target Price $28
Oppenheimer Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $32
Wedbush Adjusts Price Target on Astria Therapeutics to $28 From $27, Keeps Outperform Rating
Astria Therapeutics Inc | 10-K: FY2024 Annual Report
Astria TherapeuticS GAAP EPS of -$1.68 Beats by $0.01